People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

This study is observing people with multiple sclerosis (MS) who are being treated with ocrelizumab (a disease-modifying therapy) and are also taking GLP-1 agonist medications (commonly used for diabetes and weight loss, such as semaglutide or liraglutide). The goal is to understand whether GLP-1 agonists might have any effect on MS disease activity or progression. **You may be eligible if...** - You are 18–70 years old with a confirmed MS diagnosis (any type) - Your BMI is 24 or above - You have received at least one dose of ocrelizumab - Your MS disability score is less than 7.0 (meaning you can still walk) - You are willing to provide informed consent and an MRI confirming your MS diagnosis **You may NOT be eligible if...** - You have previously received aggressive MS treatments such as Lemtrada, Mavenclad, cyclophosphamide, or stem cell transplant - You are currently in another clinical trial - You had a relapse in the last 3 months - You have had major surgery in the past 6 months or taken systemic steroids in the past 3 months - You have not been on ocrelizumab for more than 9 months - You are unable to communicate in a language the hospital can support Talk to your doctor to see if this trial is right for you.